CONGRATULATIONS TO LENSGEN TEAM ON THIS SIGNIFICANT MILESTONE: IDE APPROVAL FROM THE U.S. FDA TO BEGIN CLINICAL STUDY

ELT SIGHT: TAKING "MINIMALLY INVASIVE" GLAUCOMA SURGERY TO NEW HEIGHTS

TREFOIL PROFILED IN OPHTHALMOLOGY BIOPHARMA DEALMAKERS

DTX SOARS TO $100 MILLION SERIES B

WALL STREET JOURNAL COVERS NEW CROP OF VENTURE FIRMS INCLUDING EXSIGHT

RE-VANA THERAPEUTICS DELIVERS $3.2 MILLION OVERSUBSCRIBED ROUND

ENVISION DIAGNOSTICS RAISES SERIES A ROUND

EXSIGHT ANNOUNCES DTX INVESTMENT TO ENABLE DELIVERY OF RNA THERAPEUTICS

ELECTRIFYING VISION: ANNOUNCING OUR INVESTMENT IN 2C TECH

INTRODUCING THE EXSIGHT VENTURES SYNDICATE ON ANGELLIST

LENSGEN IS THE TALK OF THE TOWN @ ASCRS 2019

HIS KIND OF TOWN: FIRAS HOSTS OIS TV AT OIS@ASRS IN CHICAGO

ANNOUNCING OUR NEXT FUND: PROOF OF CONCEPT

TREFOIL MOVES CLOSER TO A CLINICAL TRIAL: ANNOUNCING OUR FOLLOW ON INVESTMENT

QURA'S PROMISE: ENABLE SMARTER TREATMENT DECISIONS BASED ON BETTER INFORMATION

ONL THERAPEUTICS IS PIONEERING AN ENTIRELY NEW APPROACH TO PRESERVING SIGHT AND HALTING VISION LOSS

EXSIGHT PARTNER ALAN SPIRO JOINS INNOVATIVE ODYLIA THERAPEUTICS

LENSGEN HITTING MILESTONES AND BROADENING PATENT PROTECTION

THE EXSIGHT VENTURES THESIS

DR. RAHHAL CO-AUTHORS BREAKTHROUGH STEM CELL TRANSPLANT TRIAL TARGETING VISION LOSS